TRANSMEDICS GROUP INC (TMDX) — insider trading
Health Care · NASDAQ
TRANSMEDICS GROUP INC (TMDX) has 20 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 1 open-market sale among the most recent 20 (latest 2026-09-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Weill David | Director | Open-market purchase | 1,336 | $81.63 | $109.1K | Form 4 |
| 2026-08-17 | TOBIN JAMES R | Director | Bona fide gift | 18,000 | — | $0 | Form 4 |
| 2026-07-10 | Hassanein Waleed H | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 112,984 | — | $0 | Form 4 |
| 2026-07-10 | Hassanein Waleed H | Director, Officer (President & CEO) | Grant / award / vesting | 49,669 | — | $0 | Form 4 |
| 2026-07-10 | Hernandez Gerardo | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 26,153 | — | $0 | Form 4 |
| 2026-07-10 | Hernandez Gerardo | Officer (Chief Financial Officer) | Grant / award / vesting | 17,246 | — | $0 | Form 4 |
| 2026-07-10 | Corcoran Nicholas | Officer (See remarks) | Grant / award / vesting (derivative) | 17,784 | — | $0 | Form 4 |
| 2026-07-10 | Corcoran Nicholas | Officer (See remarks) | Grant / award / vesting | 11,727 | — | $0 | Form 4 |
| 2026-06-15 | Gunderson Thomas J. | Director | Option exercise / conversion (derivative) | 19,285 | — | $0 | Form 4 |
| 2026-06-15 | Gunderson Thomas J. | Director | Open-market sale | 9,624 | $75.06 | $722.4K | Form 4 |
| 2026-06-15 | Gunderson Thomas J. | Director | Option exercise / conversion | 19,285 | $2.21 | $42.6K | Form 4 |
| 2026-05-20 | Kania Edwin | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-20 | TOBIN JAMES R | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-20 | Basile Edward M | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-20 | Gunderson Thomas J. | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-20 | RAINES MERILEE | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-20 | Weill David | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-20 | Lovell Stephanie | Director | Grant / award / vesting | 2,922 | — | $0 | Form 4 |
| 2026-05-19 | Forsyth Matthew S. | Officer (See Remarks) | Grant / award / vesting (derivative) | 23,171 | — | $0 | Form 4 |
| 2026-05-19 | Forsyth Matthew S. | Officer (See Remarks) | Grant / award / vesting | 15,409 | — | $0 | Form 4 |
Ask the chat about TMDX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TRANSMEDICS GROUP INC (TMDX).
Last updated 2026-09-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.